Workflow
ACADIA Pharmaceuticals(ACAD) - 2025 Q1 - Quarterly Results
ACADACADIA Pharmaceuticals(ACAD)2025-05-07 20:13

Financial Performance - Total revenues for the first quarter of 2025 were 244.3million,representinga19244.3 million, representing a 19% increase year-over-year[1] - NUPLAZID® net product sales reached 159.7 million, up 23% compared to 129.9millioninthefirstquarterof2024[6]−DAYBUE®netproductsaleswere129.9 million in the first quarter of 2024[6] - DAYBUE® net product sales were 84.6 million, an 11% increase from 75.9millioninthesamequarterlastyear[7]−Netincomeforthefirstquarterof2025was75.9 million in the same quarter last year[7] - Net income for the first quarter of 2025 was 19.0 million, or 0.11pershare,comparedto0.11 per share, compared to 16.6 million, or 0.10pershare,forthesameperiodin2024[10]RevenueGuidance−Thecompanyexpectsfullyear2025revenueguidanceof0.10 per share, for the same period in 2024[10] Revenue Guidance - The company expects full year 2025 revenue guidance of 1.03 to 1.095billion,withNUPLAZIDnetsalesprojectedbetween1.095 billion, with NUPLAZID net sales projected between 650 to 690millionandDAYBUEnetsalesbetween690 million and DAYBUE net sales between 380 to 405million[13]Expenses−Researchanddevelopmentexpensesincreasedto405 million[13] Expenses - Research and development expenses increased to 78.3 million from 59.7millioninthefirstquarterof2024,primarilyduetocostsfromclinicalstageprograms[8]−Selling,generalandadministrativeexpensesroseto59.7 million in the first quarter of 2024, primarily due to costs from clinical stage programs[8] - Selling, general and administrative expenses rose to 126.4 million from 108.0millioninthesameperiodlastyear,drivenbycostsrelatedtotheconsumeractivationprogramforNUPLAZID[9]PatientMetrics−Thecompanyachievedarecordhighof954uniquepatientsreceivingDAYBUEshipmentsinthefirstquarter[5]FuturePlans−AcadiaplanstosubmitaNewDrugApplicationforACP−101inthefirstquarterof2026,pendingpositiveresultsfromtheCOMPASSPWSPhase3studyexpectedinearlyQ42025[5]CashPosition−Cash,cashequivalents,andinvestmentsecuritiestotaled108.0 million in the same period last year, driven by costs related to the consumer activation program for NUPLAZID[9] Patient Metrics - The company achieved a record high of 954 unique patients receiving DAYBUE shipments in the first quarter[5] Future Plans - Acadia plans to submit a New Drug Application for ACP-101 in the first quarter of 2026, pending positive results from the COMPASS PWS Phase 3 study expected in early Q4 2025[5] Cash Position - Cash, cash equivalents, and investment securities totaled 681.6 million as of March 31, 2025, down from $756.0 million at the end of 2024[11]